Anugerah 88

159.56

-3.42

|(-2.10%)

52W H: 20052W L: 70.8Beta: -1.19

About Belite Bio Inc

Industry: Pharmaceuticals
Exchange: NASDAQ NMS - GLOBAL MARKET
Country: US
Website: https://belitebio.com/

Frequently Asked Questions

What is the 52-week range for BLTE?

The 52-week high is $200 and the 52-week low is $70.8.

What is the P/E ratio for BLTE?

The P/E ratio data is currently unavailable.

What is the dividend yield for BLTE?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -26.87%.

What is the Net Profit Margin?

Net Margin data is currently unavailable.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 7.28.

Analyst Recommendation Trends

Wall Street analyst consensus for BLTE over the last few months:

2026-09-01

Buy: 9

S.Buy: 4

Hold: 1

Sell: 0

2026-08-01

Buy: 9

S.Buy: 4

Hold: 1

Sell: 0

2026-07-01

Buy: 9

S.Buy: 4

Hold: 1

Sell: 0

2026-06-01

Buy: 9

S.Buy: 4

Hold: 1

Sell: 0

Latest BLTE News

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Innovate Retina conference being held on October 8, 2026, in New Orleans, Louisiana, and at the American Academy of Ophthalmology (AAO) 2026 being held on October 9-12, 2

Yahoo10/1/2026

Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Belite Bio, Inc (BLTE) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:45 AM EDTCompany ParticipantsHao-Yuan Chuang - CFO &...

SeekingAlpha9/14/2026

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Yahoo9/9/2026

Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.

Benzinga9/9/2026

Belite Bio On Track For A Potential Blockbuster Launch In 2027

Belite Bio is on track toward a potential blockbuster launch of tinlarebant in 2027, with FDA approval for STGD1 expected. Learn why BLTE stock is a hold.

SeekingAlpha9/9/2026

HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.

Benzinga9/8/2026

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 and could become the first Sakigake pharmaceutical product for ophthalmology disease in Japan SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite

Yahoo9/8/2026

Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1

Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss.

Benzinga9/8/2026

UiPath downgraded, Shell upgraded: Wall Street's top analyst calls

Yahoo9/4/2026

Why Is Belite Bio Stock Soaring Friday?

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.

Benzinga9/4/2026

Here Are Friday’s Top Wall Street Analyst Research Calls: Ambarella, Cal-Maine Foods, Lennar, Ormat Technologies, Paychex, PulteGroup, Shell plc, TotalEnergies, W.P. Carey, and More

Wall Street wrapped a turbulent week with a wave of upgrades and downgrades hitting energy giants, homebuilders, and tech names just ahead of the Labor Day weekend. Find out which stocks analysts are rushing to buy and which ones just lost their support.

Yahoo9/4/2026

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.

Benzinga9/4/2026

Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.

Benzinga9/4/2026

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date. At the company’s 2026 Commercial Day, Chairman and CEO

Yahoo9/3/2026

Related Stocks (Peers)

Companies operating in similar sectors to BLTE:

CORT ELAN AXSM BLTE AMRX LGND DFTX MANE EWTX LLY

Recent Insider Transactions

Date	Name	Shares Changed	Price	Value
2026-09-08	Lin Yu-Hsin	-2,700	$198.0907	$534,845
2026-09-08	Lin Yu-Hsin	-8,752	$197.3577	$1,727,275
2026-09-08	Lin Yu-Hsin	-6,058	$196.5405	$1,190,642
2026-09-08	Lin Yu-Hsin	-6,090	$195.6199	$1,191,325
2026-09-08	Lin Yu-Hsin	-2,400	$194.3328	$466,399
2026-09-08	Chuang Hao-Yuan	-2,562	$198.0454	$507,392
2026-09-08	Chuang Hao-Yuan	-4,605	$197.2299	$908,244
2026-09-08	Chuang Hao-Yuan	-4,475	$196.4692	$879,200
2026-09-08	Chuang Hao-Yuan	-4,120	$195.6041	$805,889
2026-09-08	Chuang Hao-Yuan	-2,200	$194.2791	$427,414
2026-09-04	Lin Yu-Hsin	-8,111	$193.1253	$1,566,439
2026-09-04	Lin Yu-Hsin	-4,209	$192.5426	$810,412
2026-09-04	Lin Yu-Hsin	-11,080	$191.147	$2,117,909
2026-09-04	Lin Yu-Hsin	-600	$190.3867	$114,232
2026-09-04	Lin Yu-Hsin	-8,955	$189.3414	$1,695,552
2026-09-04	Lin Yu-Hsin	-3,045	$188.2604	$573,253
2026-09-04	Lin Yu-Hsin	-6,200	$187.2523	$1,160,964
2026-09-04	Lin Yu-Hsin	-7,800	$186.3235	$1,453,323
2026-09-04	Lin Yu-Hsin	-4,593	$185.3443	$851,286
2026-09-04	Lin Yu-Hsin	-6,252	$184.5244	$1,153,647
2026-09-04	Lin Yu-Hsin	-4,955	$183.2953	$908,228
2026-09-04	Lin Yu-Hsin	-3,413	$182.499	$622,869
2026-09-04	Lin Yu-Hsin	-2,587	$181.2434	$468,877
2026-09-04	Lin Yu-Hsin	-2,635	$180.2927	$475,071
2026-09-04	Chuang Hao-Yuan	-4,602	$193.1176	$888,727
2026-09-04	Chuang Hao-Yuan	-3,398	$192.4038	$653,788
2026-09-04	Chuang Hao-Yuan	-6,200	$191.0893	$1,184,754
2026-09-04	Chuang Hao-Yuan	-1,800	$190.6331	$343,140
2026-09-04	Chuang Hao-Yuan	-6,200	$189.2244	$1,173,191
2026-09-04	Chuang Hao-Yuan	-1,900	$188.5884	$358,318
2026-09-04	Chuang Hao-Yuan	-3,900	$187.1645	$729,942
2026-09-04	Chuang Hao-Yuan	-4,600	$186.345	$857,187
2026-09-04	Chuang Hao-Yuan	-3,872	$185.2809	$717,408
2026-09-04	Chuang Hao-Yuan	-3,569	$184.5737	$658,744
2026-09-04	Chuang Hao-Yuan	-3,759	$183.2666	$688,899
2026-09-04	Chuang Hao-Yuan	-2,000	$182.4926	$364,985
2026-09-04	Chuang Hao-Yuan	-2,000	$181.0533	$362,107
2026-09-04	Chuang Hao-Yuan	-1,633	$180.1597	$294,201
2026-08-12	Chuang Hao-Yuan	-223	$180.57	$40,267
2026-08-12	Chuang Hao-Yuan	-144	$180	$25,920
2026-08-12	Lin Yu-Hsin	-223	$180.57	$40,267
2026-08-12	Lin Yu-Hsin	-142	$180	$25,560
2026-06-18	Scholl Hendrik Peter	-96	$147.11	$14,123
2026-06-18	Scholl Hendrik Peter	-1,199	$146.2449	$175,348
2026-06-18	Scholl Hendrik Peter	-4,861	$145.4348	$706,959
2026-06-18	Scholl Hendrik Peter	-3,748	$144.6617	$542,192
2026-06-18	Scholl Hendrik Peter	-96	$143.9	$13,814
2026-05-07	MATA NATHAN L.	-9	$155.2533	$1,397
2026-05-07	MATA NATHAN L.	-3	$154.61	$464
2026-05-07	MATA NATHAN L.	-428	$153.5635	$65,725
2026-05-07	MATA NATHAN L.	-226	$152.4473	$34,453
2026-05-06	MATA NATHAN L.	-100	$156	$15,600
2026-05-06	MATA NATHAN L.	-100	$155.97	$15,597
2026-05-06	MATA NATHAN L.	-240	$154.4117	$37,059
2026-05-06	MATA NATHAN L.	-128	$153.4183	$19,638
2026-05-06	MATA NATHAN L.	-424	$152.6717	$64,733
2026-05-06	MATA NATHAN L.	-8	$151.57	$1,213
2026-05-05	MATA NATHAN L.	-68	$158.11	$10,751
2026-05-05	MATA NATHAN L.	-155	$157.2897	$24,380
2026-05-05	MATA NATHAN L.	-121	$156.5292	$18,940
2026-05-05	MATA NATHAN L.	-173	$155.4771	$26,898
2026-05-05	MATA NATHAN L.	-363	$154.4433	$56,063
2026-05-05	MATA NATHAN L.	-120	$153.9217	$18,471
2026-05-04	MATA NATHAN L.	-172	$157.4904	$27,088
2026-05-04	MATA NATHAN L.	-235	$156.5677	$36,793
2026-05-04	MATA NATHAN L.	-325	$155.206	$50,442
2026-05-04	MATA NATHAN L.	-236	$154.2375	$36,400
2026-05-04	MATA NATHAN L.	-32	$153.495	$4,912
2026-05-01	MATA NATHAN L.	-23	$160	$3,680
2026-05-01	MATA NATHAN L.	-38	$159.0784	$6,045
2026-05-01	MATA NATHAN L.	-65	$158.348	$10,293
2026-05-01	MATA NATHAN L.	-106	$157.4518	$16,690
2026-05-01	MATA NATHAN L.	-82	$156.2415	$12,812
2026-05-01	MATA NATHAN L.	-346	$155.476	$53,795
2026-05-01	MATA NATHAN L.	-288	$154.3797	$44,461
2026-05-01	MATA NATHAN L.	-52	$153.8942	$8,002
2026-04-30	MATA NATHAN L.	-101	$158.1453	$15,973
2026-04-30	MATA NATHAN L.	-340	$157.3717	$53,506
2026-04-30	MATA NATHAN L.	-517	$156.5866	$80,955
2026-04-30	MATA NATHAN L.	-42	$155.6767	$6,538
2026-04-29	MATA NATHAN L.	-22	$158.1941	$3,480
2026-04-29	MATA NATHAN L.	-102	$157.3859	$16,053
2026-04-29	MATA NATHAN L.	-339	$156.4304	$53,030
2026-04-29	MATA NATHAN L.	-259	$155.5228	$40,280
2026-04-29	MATA NATHAN L.	-278	$154.578	$42,973
2026-04-28	MATA NATHAN L.	-54	$162.1424	$8,756
2026-04-28	MATA NATHAN L.	-89	$161.7207	$14,393
2026-04-28	MATA NATHAN L.	-120	$160.2742	$19,233
2026-04-28	MATA NATHAN L.	-380	$159.4192	$60,579
2026-04-28	MATA NATHAN L.	-62	$158.7107	$9,840
2026-04-28	MATA NATHAN L.	-222	$157.487	$34,962
2026-04-28	MATA NATHAN L.	-53	$156.6117	$8,300
2026-04-28	MATA NATHAN L.	-8	$155.3588	$1,243
2026-04-28	MATA NATHAN L.	-12	$154.6467	$1,856
2026-04-27	MATA NATHAN L.	-36	$164.0717	$5,907
2026-04-27	MATA NATHAN L.	-409	$163.5573	$66,895
2026-04-27	MATA NATHAN L.	-231	$162.3775	$37,509
2026-04-27	MATA NATHAN L.	-280	$161.6211	$45,254
2026-04-27	MATA NATHAN L.	-44	$160.8345	$7,077
2026-04-24	MATA NATHAN L.	-3	$162.53	$488
2026-04-24	MATA NATHAN L.	-28	$161.2216	$4,514
2026-04-24	MATA NATHAN L.	-330	$160.3979	$52,931
2026-04-24	MATA NATHAN L.	-375	$159.4601	$59,798
2026-04-24	MATA NATHAN L.	-190	$158.6468	$30,143
2026-04-24	MATA NATHAN L.	-74	$157.8646	$11,682
2026-04-23	MATA NATHAN L.	-21	$169.5567	$3,561
2026-04-23	MATA NATHAN L.	-54	$168.4339	$9,095
2026-04-23	MATA NATHAN L.	-373	$167.3743	$62,431
2026-04-23	MATA NATHAN L.	-127	$166.5609	$21,153
2026-04-23	MATA NATHAN L.	-158	$165.3759	$26,129
2026-04-23	MATA NATHAN L.	-267	$164.4734	$43,914
2026-04-22	MATA NATHAN L.	-21	$173.041	$3,634
2026-04-22	MATA NATHAN L.	-249	$172.4901	$42,950
2026-04-22	MATA NATHAN L.	-257	$171.615	$44,105
2026-04-22	MATA NATHAN L.	-75	$170.5833	$12,794
2026-04-22	MATA NATHAN L.	-105	$169.5236	$17,800
2026-04-22	MATA NATHAN L.	-101	$168.6355	$17,032
2026-04-22	MATA NATHAN L.	-141	$167.4206	$23,606
2026-04-22	MATA NATHAN L.	-20	$166.32	$3,326
2026-04-22	MATA NATHAN L.	-31	$165.701	$5,137
2026-04-21	Lin Yu-Hsin	+10,000	-	-
2026-04-21	Scholl Hendrik Peter	+10,000	-	-
2026-04-21	Chuang Hao-Yuan	+10,000	-	-
2026-04-21	MATA NATHAN L.	-214	$167.3386	$35,810
2026-04-21	MATA NATHAN L.	-312	$166.4858	$51,944
2026-04-21	MATA NATHAN L.	-332	$165.4935	$54,944
2026-04-21	MATA NATHAN L.	-78	$164.6006	$12,839
2026-04-21	MATA NATHAN L.	-64	$163.4948	$10,464
2026-04-20	MATA NATHAN L.	-9	$168.35	$1,515
2026-04-20	MATA NATHAN L.	-16	$167.165	$2,675
2026-04-20	MATA NATHAN L.	-3	$166.905	$501
2026-04-20	MATA NATHAN L.	-40	$165.2935	$6,612
2026-04-20	MATA NATHAN L.	-124	$164.4009	$20,386
2026-04-20	MATA NATHAN L.	-524	$163.5193	$85,684
2026-04-20	MATA NATHAN L.	-284	$162.7552	$46,222
2026-04-17	MATA NATHAN L.	-200	$163.325	$32,665
2026-04-17	MATA NATHAN L.	-216	$162.4833	$35,096
2026-04-17	MATA NATHAN L.	-274	$161.4092	$44,226
2026-04-17	MATA NATHAN L.	-226	$160.5474	$36,284
2026-04-17	MATA NATHAN L.	-52	$159.3838	$8,288
2026-04-17	MATA NATHAN L.	-32	$158.4563	$5,071
2026-04-16	MATA NATHAN L.	-12	$164.1233	$1,969
2026-04-16	MATA NATHAN L.	-36	$163.2111	$5,876
2026-04-16	MATA NATHAN L.	-76	$162.2638	$12,332
2026-04-16	MATA NATHAN L.	-240	$161.6097	$38,786
2026-04-16	MATA NATHAN L.	-201	$160.3475	$32,230
2026-04-16	MATA NATHAN L.	-219	$159.8132	$34,999
2026-04-16	MATA NATHAN L.	-216	$158.2784	$34,188
2026-04-15	MATA NATHAN L.	-4	$171.19	$685
2026-04-15	MATA NATHAN L.	-8	$170.765	$1,366
2026-04-15	MATA NATHAN L.	-68	$169.1524	$11,502
2026-04-15	MATA NATHAN L.	-537	$168.6444	$90,562
2026-04-15	MATA NATHAN L.	-383	$167.5792	$64,183
2026-04-09	Lin Yu-Hsin	-200	$183	$36,600
2026-04-09	Lin Yu-Hsin	-3,000	$182.396	$547,188
2026-04-09	Lin Yu-Hsin	-3,500	$181.3304	$634,656
2026-04-09	Lin Yu-Hsin	-2,500	$180.3578	$450,895
2026-04-09	Chen Wan-Shan	-1,100	$180.4301	$198,473
2026-04-09	Chuang Hao-Yuan	-291	$183.0813	$53,277
2026-04-09	Chuang Hao-Yuan	-1,909	$182.5782	$348,542
2026-04-09	Chuang Hao-Yuan	-2,000	$181.395	$362,790
2026-04-09	Chuang Hao-Yuan	-2,000	$180.3475	$360,695
2026-03-31	Chen Wan-Shan	+13,796	-	-
2026-03-31	Chuang Hao-Yuan	+144,868	-	-
2026-03-31	MATA NATHAN L.	+144,868	-	-
2026-03-31	Lin Yu-Hsin	+206,954	-	-